Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 2, 2010, Pages 228-230

  Bagazgoitia, L ^a   Cuevas, J ^b   Juarranz, A ^c  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Actinic keratosis; Bowen's disease; Bowenoid actinic keratosis; P16

Indexed keywords

PROTEIN P16; PROTEIN P53;

ACTINIC KERATOSIS; ARTICLE; BIOPSY; BOWEN DISEASE; BOWENOID PAPULOSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EPIDERMIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BIOPSY; BOWEN'S DISEASE; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; KERATOSIS, ACTINIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 74549220784     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03337.x     Document Type: Article

References (14)

1. Mortier L, Marchetti P, Delaporte E et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16 (INK4a) tumor suppressor. Cancer Lett 2002 176 : 205 214.
2. Hansen JP, Drake AL, Walling HW. Bowen's disease: a four-year retrospective review of epidemiology and treatment at a university center. Dermatol Surg 2008 34 : 878 883.
3. Salama ME, Mahmood MN, Qureshi HS, Ma C, Zarbo RJ, Ormsby AH. p16INK4a expression in actinic keratosis and Bowen's disease. Br J Dermatol 2003 149 : 1006 1012.
4. van der Pols JC, Xu C, Boyle GM, Parsons PG, Whiteman DC, Green AC. Expression of p53 tumor suppressor protein in sun-exposed skin and associations with sunscreen use and time spent outdoors: a community-based study. Am J Epidemiol 2006 163 : 982 988.
5. Stratigos AJ, Kapranos N, Petrakou E et al. Immunophenotypic analysis of the p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation. J Eur Acad Dermatol Venereol 2005 19 : 180 186.
6. Kim KH, Park EJ, Seo YJ et al. Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors. J Dermatol 2006 33 : 319 325.
7. Saglam O, Salama M, Meier F et al. Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin. Am J Dermatopathol 2008 30 : 123 126.
8. Nindl I, Gottschling M, Krawtchenko N et al. Low prevalence of p53, 16 (INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis. Br J Dermatol 2007 156 (Suppl. 3 34 39.
9. Soufir N, Moles JP, Vilmer C et al. P16 UV mutations in human skin epithelial tumors. Oncogene 1999 18 : 5477 5481.
10. Conscience I, Jovenin N, Coissard C et al. P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas. Eur J Dermatol 2006 16 : 518 522.
11. Hodges A, Smoller BR. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin. Mod Pathol 2002 15 : 1121 1125.
12. Willman JH, Heinz D, Golitz LE, Shroyer KR. Correlation of p16 and pRb expression with HPV detection in Bowen's disease. J Cutan Pathol 2006 33 : 629 633.
13. Chang CH, Tsai RK, Chen GS, Yu HS, Chai CY. Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers. J Cutan Pathol 1998 25 : 457 462.
14. Ramzi ST, Maruno M, Khaskhely NM et al. An assessment of the malignant potential of actinic keratoses and Bowen's disease: p53 and PCNA expression pattern correlate with the number of desmosomes. J Dermatol 2002 29 : 562 572.